← Stock Trading Canary · All insider profiles
INSIDER PROFILE · SE
Petter Segelman Lindqvist
Verkställande direktör (VD)
Profile key: se|petter segelman lindqvist
Purchase history
- Companies traded
- 1
- Purchases · 12M
- 1
- Purchases · 24M
- 4
- Average purchase
- SEK 153,665
- Gross purchase value
- SEK 614,661
- Last purchase
- 2026-03-30
- Completed 20D events
- 3.0
- Outcome status
- INSUFFICIENT_SAMPLE
Latest company: Isofol Medical AB (publ)
Companies: Isofol Medical AB (publ)
Post-purchase outcomes
Benchmark-relative outcomes are available against OMX Stockholm 30.
- Excess return = stock return − OMX Stockholm 30 return over the same period.
- Hit rate = positive excess-return events ÷ completed events.
- Price coverage = valid point-in-time prices ÷ events mature enough for that period.
- Returns start on the first shared trading session on or after publication.
| Period | Completed events | Price coverage | Hit rate | Median excess return | Average excess return | Worst excess return |
|---|---|---|---|---|---|---|
| 5D | 3Small sample | 100.0% (3/3) | 66.7% (2/3) | +2.6% | +1.5% | -2.1% |
| 20D | 3Small sample | 100.0% (3/3) | 66.7% (2/3) | +4.1% | +4.0% | -0.8% |
| 60D | 3Small sample | 100.0% (3/3) | 33.3% (1/3) | -10.6% | -7.6% | -16.2% |
| 120D | 3Small sample | 100.0% (3/3) | 33.3% (1/3) | -30.1% | -20.0% | -36.1% |
Research patterns
- First purchase in 12M
- 1/1
- Large purchase ≥ €100k
- 0/3
- Cluster buying · 15D
- 1/3
- Buying the dip · ≥20% below prior 52W high
- 3/3
- Routine / opportunistic
- Not classifiable
Counts are profile-wide, point-in-time research labels. They never affect the insider score or ranking.
Every completed outcome is shown; n<5 is descriptive small-sample evidence and is not scored. Disclosure-level observations published on the same date may share a return path and may not be statistically independent. These results never affect the insider score or ranking.